Quarterly report pursuant to Section 13 or 15(d)

Schedule of Accrued Expenses (Details) (Parenthetical)

v3.23.3
Schedule of Accrued Expenses (Details) (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended
Dec. 31, 2022
Apr. 08, 2022
Mar. 31, 2023
Sep. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Deferred liability [1] $ 88    
BioNTech Agreement [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue recognized 688 $ 2,750 $ 688  
Genentech Agreement [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue recognized 33      
CFF Agreement [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Deferred liability $ 88      
[1] At December 31, 2022, the balances of $88 related to an award agreement with the Cystic Fibrosis Foundation (the “CFF Agreement). (See Note 9 – Revenue Recognition, Collaboration Agreements and Other).